Credit: Getty Images. Researchers conducted pooled analysis of the COUGH-1 and COUGH-2 phase 3 trials of gefapixant for treating refractory/unexplained chronic cough. In phase 3 randomized clinical ...
(RTTNews) - Merck & Co. Inc. (MRK) on Tuesday announced the results from two pivotal Phase 3 trials, COUGH-1 and COUGH-2, evaluating the efficacy and safety of gefapixant (MK-7264) for the potential ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the ...
There are currently no FDA-approved treatments for refractory chronic cough or unexplained chronic cough. At the CHEST Annual Meeting 2021, attendees heard a readout from a durability study as well as ...
MANCHESTER, England & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive ...
Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests. Researchers found the combination of the cough suppression test and the cough challenge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results